TYVYT®: Sintilimab Injection

In China, sintilimab has been approved for seven indications and included in the National Reimbursement Drug List (NRDL) for six indications. In January 2023, TYVYT® has been included in the NRDL for two additional indications including gastric cancer and esophageal cancer. TYVYT® is the first and the only PD-1 inhibitor for gastric cancer in the NRDL, as well as the only PD-1 inhibitor for the first-line treatment of five high-incidence cancer types in the NRDL.